ProCE Banner Activity

CAPELLA: Wk 52 Results With Long-acting SC Lenacapavir in Persons With Multidrug-Resistant HIV

Slideset Download
Conference Coverage
Lenacapavir in combination with an optimized background regimen associated with virologic suppression in 83% of patients, 1 injection site reaction leading to discontinuation.

Released: February 17, 2022

Expiration: February 16, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare